EUVIMEDEUVIMED entdecken
Crossref

Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease

Catherine C Go, Frank Annie, Kerry Drabish, Mohammad H Eslami

Journal of Vascular Surgery · 2025

DOI: 10.1016/j.jvs.2025.05.037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Vascular Surgery, 2025. Verfasst von Catherine C Go und 3 weiteren Autor:innen. Beteiligte Einrichtung: Charleston Area Medical Center, Vascular Center of Excellence, Charleston, WV. Electronic address: catherine.go@vandaliahealth.org. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Incretins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Patients with peripheral arterial disease (PAD) and diabetes mellitus have significantly higher rates of cardiovascular mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RA)-such as tirzepatide and semaglutide-have been shown to decrease rates of major adverse cardiac events (MACEs) and mortality in patients with diabetes mellitus. However, their effect on limb outcomes in patients with PAD has yet to be investigated. The aim of this study was to explore the impact of GLP-1RAs on cardiovascular outcomes in patients with moderate PAD. METHODS: Data were sourced from the TriNetX research network, encompassing more than 1002 health care organizations. We used a one:one propensity-matched study to compare patients with an ankle-brachial index (ABI) of 0.4-0.9 who were started on GLP-1RA (group 1) with those patients who were not started on a GLP-1RA (group 2). Patients with chronic wounds or with an ABI outside of this range were excluded. MACEs were defined as myocardial infarction, stroke, acute ischemic heart disease, and heart failure. Major adverse limb events (MALEs) were defined as acute limb ischemia requiring thrombectomy or major amputation. Any inpatient admission, MACE, and MALE were identified using International Classification of Diseases, 10the edition, codes. Standard statistical methods were used as appropriate. RESULTS: We identified 858,750 patients with moderate PAD between October 1, 2022, and December 31, 2023. After matching for age, sex, diabetes status, smoking history, and coronary artery disease, each group included 55,041 patients. Group 1 had a higher starting weight (216 ± 56.8 lb versus 188 ± 51.5 lb; P = .0001) and baseline hemoglobin A1C (7.2 ± 1.8 versus 6.7 ± 1.7; P = .01). The baseline ABI was 0.73 ± 0.29 in group 1 and 0.88 ± 0.26 in group 2 (P = .07). At 1 year, there were fewer mortalities (1.7% versus 4.4%; P < .01), MACEs (25.4% versus 29.3%; P < .01), MALEs (0.8% versus 1.5%; P < .01), and inpatient hospitalizations (17.9% versus 26.8%; P < .01) in group 1. On multivariate analysis, GLP-1RAs significantly reduced the risk of MACEs (hazard ratio, 0.87; 95% CI, 0.85-0.89; P = .01), MALEs (hazard ratio, 0.57; 95% confidence interval [CI], 0.51-0.64; P = .02), and inpatient admission (odds ratio, 0.64; 95% CI, 0.62-0.66; P = .01) and complications (odds ratio, 0.67; 95% CI, 0.65-0.68; P = .01). CONCLUSIONS: The use of GLP-1RAs in patients with moderate PAD is associated with a decreased rate of MACEs and MALEs. Patients on GLP-1RAs are at a decreased risk of mortality, inpatient hospitalizations, and inpatient complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsHumansMaleFemaleAgedRisk FactorsTreatment OutcomeMiddle AgedTime FactorsRisk AssessmentRetrospective StudiesAmputation, SurgicalAged, 80 and overSeverity of Illness IndexDatabases, FactualLimb Salvage

Stichwörter der Autor:innen

AmputationGLP-1 receptor agonistMACEMALEPeripheral arterial disease

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretins

Autor:innen und Institutionen

  • Charleston Area Medical Center, Vascular Center of Excellence, Charleston, WV. Electronic address: catherine.go@vandaliahealth.org.
  • Charleston Area Medical Center, Vascular Center of Excellence, Charleston, WV.

Zitieren

APA

Go, C. C., Annie, F., Drabish, K., & Eslami, M. H. (2025). Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2025.05.037

Vancouver

Go CC, Annie F, Drabish K, Eslami MH. Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease. Journal of Vascular Surgery. 2025. doi:10.1016/j.jvs.2025.05.037

BibTeX
@article{Go2025,
  author = {Go, Catherine C and Annie, Frank and Drabish, Kerry and Eslami, Mohammad H},
  title = {Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease},
  journal = {Journal of Vascular Surgery},
  year = {2025},
  doi = {10.1016/j.jvs.2025.05.037}
}
Kostenlos starten →